Dr. Ian J. Bristol, MD

Dr. Bristol practices at New England Cancer Specialists in Scarborough, Maine.

Dr. Bristol's NPI, 1235357294, was assigned on April 23, 2007. Dr. Bristol graduated from University of Rochester School of Medicine and Dentistry in 2002. Dr. Bristol holds Maine license MD17399.

Dr. Bristol's primary practice is New England Cancer Specialists, at 51 State Rte 1, Scarborough, ME 04074 in Cumberland County. The practice phone is (207) 303-3000.

Dr. Bristol's primary practice is New England Cancer Specialists in Scarborough, Maine. Dr. Bristol is also affiliated with MaineHealth Maine Medical Center. The medical group on file is New England Cancer Specialists. Dmand AI also links Dr. Bristol to 4 more hospitals and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bristol practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Bristol's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Bristol's licenses on file in 2 states: Maine and New Hampshire.

CMS data shows 1,486 Medicare services from Dr. Bristol across 16 procedure codes in 2024, for 299 Medicare patients. Medicare paid $95,252 for them.

CMS counts 299 Medicare patients who saw Dr. Bristol in 2024. The largest group is 65 to 74, with 140 patients. 75% of them have cancer, and 69% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bristol's median patient age at 72, with 49% women.

In 2024, Dr. Bristol wrote 200 Medicare Part D claims for 86 patients. 89% of them were for generic drugs. CMS names the drug for 157 of them, across 4 drugs with 11 or more claims each, at $966 in total drug cost. In 2023, CMS named 123 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Bristol for performance year 2024, reported through an alternative payment model (APM). Dr. Bristol accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 2 papers to Dr. Bristol, published from 2014 to 2019. Dr. Bristol's most frequent co-authors are Timothy Louis Fitzgerald, MD and Dougald C. Macgillivray, MD.

Dmand AI links Dr. Bristol to 3 clinical trials, 2 of them phase 2 studies. Conditions studied include Carcinoma, Non-Small-Cell Lung, Urinary Bladder Neoplasms and Uterine Cervical Neoplasms.

CMS Open Payments shows 6 general payments to Dr. Bristol from 6 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 100% of the total. Incyte Corporation paid the most, $24.

Dr. Bristol graduated from University of Rochester School of Medicine and Dentistry in 2002.